131179-95-8 Usage
Description
Efaproxiral, also known as an allosteric hemoglobin (Hb) modifier, is a compound that reduces the affinity of Hb for oxygen, thereby increasing the diffusion of oxygen from blood to tissue. It is characterized by its off-white to tan solid appearance and plays a significant role in enhancing oxygen delivery to tissues, particularly in hypoxic conditions.
Uses
Used in Anticancer Applications:
Efaproxiral is used as an antineoplastic adjunct (radiosensitizer) for enhancing radiation-induced cytotoxicity in cancer cells grown under hypoxic conditions. It increases radiosensitization and inhibits tumor growth in hypoxic tumor models when administered at specific doses.
Used in Enhancing Oxygen Delivery:
Efaproxiral is used as an allosteric modifier of hemoglobin (HB) to increase the partial pressure of oxygen at which Hb is 50% saturated (p50) and decrease the percent oxyhemoglobin (Hb-O2) saturation at a given partial oxygen pressure (pO2). This modification improves oxygen delivery to tissues, which can be beneficial in various medical conditions where oxygen supply is compromised.
Used in Cardiovascular Applications:
Efaproxiral is used to increase the running capacity of normal mice and mice with left coronary artery (LCA) ligation-induced myocardial infarction (MI) when administered at a specific dose. This application highlights its potential in improving oxygen supply to the heart and enhancing cardiac function in certain conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 131179-95-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,1,7 and 9 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 131179-95:
(8*1)+(7*3)+(6*1)+(5*1)+(4*7)+(3*9)+(2*9)+(1*5)=118
118 % 10 = 8
So 131179-95-8 is a valid CAS Registry Number.
InChI:InChI=1/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)
131179-95-8Relevant articles and documents
Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral
Gustafsson, Tomas,Ponten, Fritiof,Seeberger, Peter H.
, p. 1100 - 1102 (2008/09/21)
A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction has been developed in a microreactor system; rimonabant and efaproxiral were prepared to illustrate the utility of the method. The Royal Society of Chemistry.
Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry
Thevis, Mario,Krug, Oliver,Schaenzer, Wilhelm
, p. 332 - 338 (2007/10/03)
Efaproxiral (2-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxyl]-2- methylpropionic acid, formerly referred to as RSR13) is prohibited in sports according to the World Anti-Doping Agency (WADA). The drug as well as structurally related compounds and a stable isotope-labeled derivative have been synthesized to elucidate the fragmentation pathway of efaproxiral, using electrospray ionization (ESI) and tandem mass spectrometry by employing a novel linear ion trap - orbitrap hybrid mass spectrometer - in positive and negative ionization modes. The elimination of 2-methyl acrylic acid (-86 u) has been identified as a major fragmentation process in both charge states. Negative ionization and collision-induced dissociation (CID) caused an additional release of carbon dioxide (-44 u), and positive ionization the loss of formic acid (-46 u). Efaproxiral was incorporated into an existing screening procedure for doping controls using solid-phase extraction (SPE) followed by liquid chromatography-tandem mass spectrometry, enabling a limit of detection of 2.5 ng/ml and interday precisions ranging from 7.9 to 13.0%. Copyright
